Stock Details
DSKYF is Daiichi Sankyo Company, Limited's stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 28.43$. Average daily volumn in 3 months 3.13k. Market cap 55.45B

Stock symbol : DSKYF. Exchange : Other OTC. Currency : USD
Lastest price : 29.24$. Total volume : 515.00. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Daiichi Sankyo Company, Limited (DSKYF)
Last Price

Previous Close28.41
Day Range29.24-29.24
Bid0.00 x N/A
Ask0.00 x N/A
Average Volume3.13k
Market Cap55.45B
52 Week Range19.45-33.64
Trailing P/E162.44
Foward P/E76.95
Dividend (Yield %)0.77%
Ex-Dividend Date2023-03-30

Financial Details

According to Daiichi Sankyo Company, Limited's financial reports the company's revenue in 2022 were 1.04T an decrease( +3.95%) over the years 2021 revenue that were of 962.52B. In 2022 the company's total earnings were 66.97B while total earnings in 2021 were 75.96B(-12%).

Loading ...


Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatm... ent; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Market Cap:
Total Assets:
Total Cash:

News about "Daiichi Sankyo Company, Limited"


Japan approves Daiichi Sankyoโ€™s Ezharmia for refractory T-cell leukemia, lymphoma

Source from : BioWorld - 7 days ago

Japanโ€™s Ministry of Health, Labor and Welfare approved Daiichi Sankyo Co. Ltd.โ€™s Ezharmia (valemetostat tosilate), the first dual inhibitor of histone methyltransferases EZH1 and EZH2 for the ...See details»

Daiichi Sankyo

Source from : PMLiVE - 1 year ago

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into ...See details»


Daiichi Sankyo joins Startup Creasphere's Program Powered by Plug and Play

Source from : Asia One - 6 days ago

Startup Creasphere, the digital healthcare platform of Plug and Play, has announced its new partnership with Daiichi Sankyo. The partnership ...See details»


IHH Healthcare in talks with Indian authorities over stalled open offer for additional 26.1 percent stake in Fortis Healthcare

Source from : Daily - 6 days ago

It further said that the order by the apex court "supports our belief that our investment into Fortis was undertaken in a fair and transparent manner".See details»

Daiichi Sankyo begins phase 3 trial of mRNA Covid-19 vaccine, DS-5670) in unvaccinated individuals in Japan

Source from : Pharmabiz - 1 month ago

As a Japanese pharmaceutical company with specialty in developing vaccines, Daiichi Sankyo is proceeding with the development of DS-5670 and will continue consultation with regulatory authorities to ...See details»


IHH in talks with Indian authorities over stalled open offer in Fortis

Source from : Business Standard - 7 days ago

Malaysia's IHH Healthcare is in discussions with relevant authorities in India to determine the next step for its stalled open offer for an additional 26.1 per cent stake in Fortis Healthcare ...See details»

Japan Pharmaceutical Market Size Is Likely to Experience a Tremendous Growth by 2031 Covid-19 Analysis

Source from : MarketWatch - 13 days ago

The Japan Pharmaceutical market studied was anticipated to show a slow growth with a CAGR of 1.06%. In Japan, the pharmaceutical industry has experienced modest growth patterns in recent years. Strong ...See details»

Daiichi Sankyo grabs first approval for blood cancer drug Ezharmia

Source from : pharmaphorum - 8 days ago

Japanโ€™s Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell ...See details»


Duality announced the appointment of Dr. Yver as Chairman of SAB

Source from : Business Insider - 1 days ago

PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ -- Duality Biotherapeutics, Inc. ('Duality' or 'the Company') today ...See details»


Former Ranbaxy Promoters Malvinder Singh, Shivinder Singh Awarded 6 Months Jail In Daiichi-Fortis Case

Source from : Outlookindia - 12 days ago

Daiichi had challenged the Fortis-IHH deal to recover the Rs 3,600 crore arbitration award it had won in a Singapore tribunal against Fortis' former promoters Malvinder and Shivinder ...See details»

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Source from : Business Insider - 14 days ago

Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMUโ€‘856 in Single and 14-Day Multiple Dosing โ€“โ€“ No ...See details»

Daiichi Sankyo submits quizartinib sNDA to Japanโ€™s MHLW for patients with newly diagnosed FLT3-ITD positive AML

Source from : Pharmabiz - 1 month ago

Daiichi Sankyo announced that it has submitted a supplemental New Drug Application (sNDA) to Japanโ€™s Ministry of Health, Labour and Welfare (MHLW) for quizartinib in combination with standard ...See details»

Gastric Ulcer Treatment Market Growth and Future Analysis : Exclusive Report by Fortune Business Insights 2022

Source from : MarketWatch - 5 days ago

The "Gastric Ulcer Treatment Market Size" industry report contains detailed information on factors influencing ...See details»

SC awards six months jail term to former promoters of Fortis Healthcare

Source from : The Week - 12 days ago

New Delhi, Sep 22 (PTI) The Supreme Court on Thursday awarded six months jail term to former promoters of Fortis Healthcare Ltd, Ma ...See details»